IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 2492 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
 
CASE REPORT
Ahead of Print

Successful treatment of metastatic extramammary Paget's disease with pemetrexed monotherapy systematically and 5-fluorouracil topically


1 Department of Oncology, Southern Medical University, Guangzhou; Department of Chemotherapy, Zhongshan People's Hospital, Zhongshan,Guangdong Province, People's Republic of China
2 Department of Chemotherapy, Zhongshan People's Hospital, Zhongshan,Guangdong Province, People's Republic of China
3 Department of Oncology, Southern Medical University, Guangzhou, People's Republic of China

Correspondence Address:
Hanlin Liang,
Department of Chemotherapy, Zhongshan People's Hospital, Zhongshan, Guangdong Province
People's Republic of China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdvl.IJDVL_171_17

PMID: 29536970

Advanced extramammary Paget's disease does not have a standardized treatment guideline as its incidence is low and has been rarely reported in literature. Here we describe a case of metastatic extramammary Paget's disease successfully treated with topical 5-fluorouracil (5-FU) and systemic pemetrexed. The therapy was safe without any appreciable adverse effects like diarrhea, rash, neutropenia or fatigue; maintaining remission for more than 6 months. Thus, we propose 5-FU and pemetrexed as the first-line therapy for advanced extramammary Paget's disease, especially for aged patients with unresectable skin lesions.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Chen K
    -  Liang H
    -  Peng J
    -  Zheng Y
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1188    
    PDF Downloaded122    

Recommend this journal

Online since 15th March '04
Published by Wolters Kluwer - Medknow